Insulin-like Growth Factor-1 Rescues the Mutated FGF Receptor 3 (G380R) Expressing ATDC5 Cells from Apoptosis Through Phosphatidylinositol 3-Kinase and MAPK

Journal of Bone and Mineral Research

Volumn 18, Issue 11, 2003, Pages 2043-2051

  Koike, Mio ^a   Yamanaka, Yoshitaka ^a   Inoue, Masaru ^a   Tanaka, Hiroyuki ^a   Nishimura, Riko ^b   Seino, Yoshiki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Achondroplasia; Apoptosis; Fibroblast growth factor receptor 3; Insulin like growth factor 1

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GROWTH HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; SOMATOMEDIN C;

ACHONDROPLASIA; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE GROWTH; CARTILAGE CELL; CELL COUNT; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DWARFISM; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GROWTH RATE; HORMONAL THERAPY; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NICK END LABELING; PROTEIN DOMAIN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BROMODEOXYURIDINE; CELL DIVISION; CELL LINE; CHONDROCYTES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 0242664637     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.11.2043     Document Type: Article

References (56)

1. De Luca F, Baron J 1999 Control of Bone growth by fibroblast growth factors. Trends Endocrinol Metab 10:61-65.
2. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A 1994 Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371:252-254.
3. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ 1994 Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335-342.
4. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ 1995 Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9:321-328.
5. Tavormina PL, Rimoin DL, Cohn DH, Zhu YZ, Shiang R, Wasmuth JJ 1995 Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet 4:2175-2177.
6. Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA 1995 A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 10:357-359.
7. Bellus GA, Bamshad MJ, Przylepa KA, Dorst J, Lee RR, Hurko O, Jabs EW, Curry CJ, Wilcox WR, Lachman RS, Rimoin DL, Francomano CA 1999 Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): Phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet 85:53-65.
8. Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donoghue DJ, Thompson LM, Francomano CA 1999 A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 64:722-731.
9. Vajo Z, Francomano CA, Wilkin DJ 2000 The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 21:23-39.
10. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P 1996 Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921.
11. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM 1996 Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12:390-397.
12. Naski MC, Wang Q, Xu J, Omitz DM 1996 Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13:233-237.
13. Webster MK, Donoghue DJ 1996 Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 15:520-527.
14. Webster MK, D'Avis PY, Robertson SC, Donoghue DJ 1996 Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16:4081-4087.
15. Naski MC, Colvin JS, Coffin JD, Omitz DM 1998 Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125:4977-4988.
16. Wang Y, Spatz MK, Kannan K, Hayk H, Avivi A, Gorivodsky M, Pines M, Yayon A, Lonai P, Givol D 1999 A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci USA 96:4455-4460.
17. Chen L, Adar R, Yang X, Monsonego EO, Li C, Hauschka PV, Yayon A, Deng CX 1999 Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J Clin Invest 104:1517-1525.
18. Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J 1998 Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 273:13007-13014.
19. Yamanaka Y, Tanaka H, Koike M, Nishimura R, Seino Y 2003 PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation. J Bone Miner Res. 18:1395-1403.
20. Shukunami C, Ishizeki K, Atsumi T, Ohta Y, Suzuki F, Hiraki Y 1997 Cellular hypertrophy and calcification of embryonal carcinoma-derived chondrogenic cell line ATDC5 in vitro. J Bone Miner Res 12:1174-1188.
21. Horton WA, Hecht JT, Hood OJ, Marshall RN, Moore WV, Hollowell JG 1992 Growth hormone therapy in achondroplasia. Am J Med Genet 42:667-670.
22. Tanaka H, Kubo T, Yamate T, Ono T, Kanzaki S, Seino Y 1998 Effect of growth hormone therapy in children with achondroplasia: Growth pattern, hypothalamic-pituitary function, and genotype. Eur J Endocrinol 138:275-280.
23. Seino Y, Moriwake T, Tanaka H, Inoue M, Kanzaki S, Tanaka T, Matsuo N, Niimi H 1999 Molecular defects in achondroplasia and the effects of growth hormone treatment. Acta Paediatr Suppl 88:118-120.
24. Daughaday WH, Hall K, Raben MS, Salmon WD Jr, Brande JLVD, Wyk JJV 1972 Somatomedin: Proposed designation for sulphation factor. Nature 235:107.
25. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C 1999 Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96:7088-7092.
26. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324-7329.
27. Daughaday WH, Rotwein P 1989 Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10:68-91.
28. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR 1997 The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272:6653-6662.
29. Foncea R, Andersson M, Ketterman A, Blakesley V, Sapag-Hagar M, Sugden PH, LeRoith D, Lavandero S 1997 Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes. J Biol Chem 272:19115-19124.
30. Parrizas M, Saltiel AR, LeRoith D 1997 Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272:154-161.
31. Sasaoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T, Usui I, Olefsky JM, Kobayashi M 1996 Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways. Endocrinology 137:4427-4434.
32. Tartare-Deckert S, Murdaca J, Sawka-Verhelle D, Holt KH, Pessin JE, Van Obberghen E 1996 Interaction of the molecular weight 85K regulatory subunit of the phosphatidylinositol 3-kinase with the insulin receptor and the insulin-like growth factor-1 (IGF-I) receptor: Comparative study using the yeast two-hybrid system. Endocrinology 137:1019-1024.
33. Thommes KB, Hoppe J, Vetter H, Sachinidis A 1996 The synergistic effect of PDGF-AA and IGF-1 on VSMC proliferation might be explained by the differential activation of their intracellular signaling pathways. Exp Cell Res 226:59-66.
34. Keegan K, Johnson DE, Williams LT, Hayman MJ 1991 Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci USA 88:1095-1099.
35. Kanai M, Goke M, Tsunekawa S, Podolsky DK 1997 Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J Biol Chem 272:6621-6628.
36. Green DR, Reed JC 1998 Mitochondria and apoptosis. Science 281:1309-1312.
37. Qu BH, Karas M, Koval A, LeRoith D 1999 Insulin receptor substrate-4 enhances insulin-like growth factor-1-induced cell proliferation. J Biol Chem 274:31179-31184.
38. Campana WM, Darin SJ, O'Brien JS 1999 Phosphatidylinositol 3-kinase and Akt protein kinase mediate IGF-I- and prosaptide-induced survival in Schwann cells. J Neurosci Res 57:332-341.
39. Morita Y, Manganaro TF, Tao XJ, Martimbeau S, Donahoe PK, Tilly JL 1999 Requirement for phosphatidylinositol-3′-kinase in cytokine-mediated germ cell survival during fetal oogenesis in the mouse. Endocrinology 140:941-949.
40. Chen H, Yan GC, Gishizky ML 1998 Identification of structural characteristics that contribute to a difference in antiapoptotic function between human insulin and insulin-like growth factor I receptors. Cell Growth Differ 9:939-947.
41. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR 1995 PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489-27494.
42. Pang L, Sawada T, Decker SJ, Saltiel AR 1995 Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 270:13585-13588.
43. Webster MK, Donoghue DJ 1997 Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol Cell Biol 17:5739-5747.
44. Seino Y, Yamanaka Y, Shinohara M, Ikegami S, Koike M, Miyazawa M, Inoue M, Moriwake T, Tanaka H 2000 Growth hormone therapy in achondroplasia. Horm Res 53(Suppl 3):53-56.
45. Barres BA, Hart IK, Coles HS, Burne JF, Voyvodic JT, Richardson WD, Raff MC 1992 Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70:31-46.
46. Gavrilovic J, Brennan A, Mirsky R, Jessen KR 1995 Fibroblast growth factors and insulin growth factors combine to promote survival of rat Schwann cell precursors without induction of DNA synthesis. Eur J Neurosci 7:77-85.
47. Dupont J, Fernandez AM, Glackin CA, Helman L, LeRoith D 2001 Insulin-like growth factor 1 (IGF-1)-induced Twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J Biol Chem 276:26699-26707.
48. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Rajo SM, Smulson ME, Yamin T, Yu VL, Miller DK 1995 Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37-43.
49. Reed JC 1995 Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541-546.
50. Herrmann JL, Bruckheimer E, McDonnell TJ 1996 Cell death signal transduction and Bcl-2 function. Biochem Soc Trans 24:1059-1065.
51. Bing OH 1994 Hypothesis: Apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 26:943-948.
52. Parrizas M, LeRoith D 1997 Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138:1355-1358.
53. Jones JI, Clemmons DR 1995 Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34.
54. Miller TM, Tansey MG, Johnson EM Jr, Creedon DJ 1997 Inhibition of phosphatidylinositol 3-kinase activity blocks depolarization- and insulin-like growth factor I-mediated survival of cerebellar granule cells. J Biol Chem 272:9847-9853.
55. Kuemmerle JF, Bushman TL 1998 IGF-I stimulates intestinal muscle cell growth by activating distinct PI 3-kinase and MAP kinase pathways. Am J Physiol 275:G151-G158.
56. Liu Q, Ning W, Dantzer R, Freund GG, Kelley KW 1998 Activation of protein kinase C-zeta and phosphatidylinositol 3′-kinase and promotion of macrophage differentiation by insulin-like growth factor-I. J Immunol 160:1393-1401.